Skip to content
lifestyle.childcarepartnerships.org
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Tech
Travel
Author:
Mineralys Therapeutics, Inc.
Mineralys Therapeutics Announces Presentation of New Data from the Phase 3 Launch-HTN Trial of Lorundrostat at the 35th European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)
May 18, 2026
Mineralys Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 6, 2026
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
May 5, 2026
Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference
May 5, 2026
Mineralys Therapeutics to Announce First Quarter 2026 Financial Results and Host Conference Call on Wednesday, May 6, 2026
April 29, 2026
Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on Thursday, March 12, 2026
March 26, 2026
Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal Officer
March 24, 2026
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
March 16, 2026
Mineralys Therapeutics Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update
March 12, 2026
Mineralys Therapeutics Announces FDA Acceptance of NDA for Lorundrostat for Treatment of Adults with Hypertension and Topline Explore-OSA Trial Results
March 9, 2026